NEW YORK (GenomeWeb) – Swedish diagnostic developer Immunovia said today that it has established a US subsidiary in Boston. The facility will house a CLIA reference lab and commercialization operations for the firm, which is preparing to launch its first test — a liquid biopsy assay for pancreatic cancer called Immray PanCan-d — in the first half of 2018.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.